### ü´Å Pulmonary Medicine: Central Sleep Apnea (CSA) Management

#### ‚úÖ True Statements
1. **Central sleep apnea (CSA)** is defined by **pauses in airflow** caused by loss of output from the **central respiratory generators in the brainstem**, resulting in **lack of respiratory effort**.
2. CSA manifests as a state of **ventilatory instability**, demonstrated by the **crescendo-decrescendo Cheyne-Stokes breathing pattern**.
3. CSA is often seen with **opioid use** and comorbid disorders, especially **heart failure (HF)** and **atrial fibrillation**.
4. Initial management of CSA should target **modifiable risk factors**, particularly **discontinuation of opioids** and **optimization of heart failure**.
5. **Adaptive servo-ventilation (ASV)** is effective at reducing the apnea-hypopnea index and improving quality of sleep in symptomatic CSA but should be **avoided in patients with left ventricular ejection fraction <45%** because of an **increased risk of death** observed in a large clinical trial.
6. **Auto-adjusting positive airway pressure (auto-PAP)** is effective for **obstructive sleep apnea (OSA)** but is **not indicated** in CSA because the **upper airway is generally patent**.
7. **Supplemental oxygen** may be used in **advanced heart failure** with hypoxemia, but it is **not indicated in CSA without hypoxemia** prior to fluid status optimization.
8. Initial treatment of CSA should target **modifiable risk factors** such as heart failure and opioid use.
9. **Positive airway pressure ventilation** prevents **upper airway collapse** in obstructive sleep apnea but is **not indicated in CSA**.

#### üí¨ Extra
4. This patient with **heart failure and volume overload** should first receive **furosemide** to optimize heart failure before considering therapies for CSA.  
5. A more recent trial of ASV in patients with CSA and heart failure did not show increased mortality, but the **sample size was small**, and prior trial results remain practice-changing.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #SleepMedicine #CentralSleepApnea #CheyneStokesBreathing #HeartFailure #Opioids #AdaptiveServoVentilation #PositiveAirwayPressure #SupplementalOxygen

#### üìö Reference
Randerath W, Verbraecken J, Andreas S, et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. *Eur Respir J*. 2017;49. PMID: 27920092 doi:10.1183/13993003.00959-2016

#### üÜî Question ID
PMMCQ24005

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Sleep Medicine, Central Sleep Apnea Syndromes, Treatment of CSA

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Sleep-related symptoms** such as awakenings, interrupted sleep, gasping, or daytime sleepiness are indications for treatment of CSA.
2. **Reduction or elimination of opioids** improves CSA.
3. **Medical optimization of heart failure** improves CSA and Cheyne-Stokes breathing.
4. **Continuous positive airway pressure (CPAP)** may occasionally be useful in CSA, especially with overlapping obstructive sleep apnea.
5. **Adaptive servo-ventilation (ASV)** is a form of bilevel positive airway pressure (BPAP) that effectively suppresses CSA.
6. Evidence is insufficient to conclude that CSA treatment improves **cardiovascular outcomes** in heart failure.
7. Two large trials of ASV in CSA with heart failure showed **no improvements in cardiovascular outcomes**, and one trial showed an **unexpected increase in mortality** in patients with reduced ejection fraction.
8. **Nocturnal oxygen** may be indicated in CSA with **hypoxemia** or in patients who cannot tolerate CPAP, but its impact on outcomes is **not well studied**.
9. An **implanted phrenic nerve stimulator** is available for CSA treatment, but more research, including comparative studies, is needed.

#### üí¨ Extra
6. The prognostic role of CSA in **heart failure** remains debated, as trials have not confirmed improved outcomes with direct CSA treatment.  
8. Unlike OSA, **oxygen therapy** may have a role in CSA but requires further study.  
9. Phrenic nerve stimulation represents a newer device-based therapy under investigation.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #SleepMedicine #CentralSleepApnea #CheyneStokesBreathing #HeartFailure #Opioids #AdaptiveServoVentilation #ContinuousPositiveAirwayPressure #OxygenTherapy #PhrenicNerveStimulator

---

#### üñºÔ∏è Supplemental Figure

<figure>
  <img src="Treat a patient with central sleep apnea.jpg" alt="Management approach for a patient with central sleep apnea" />
  <figcaption><strong>Treat a Patient with Central Sleep Apnea.</strong>Therapeutic considerations for CSA, include risk factor modification, heart failure optimization, and device-based therapy considerations.</figcaption>
</figure>
